Puma Biotechnology

Puma Biotechnology will host a conference call on Nov 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST, following Q3 2024 financial results release. The call can be accessed via phone or webcast on their website, with a replay available for 90 days.

Zacks Research raised Puma Biotechnology's FY2026 EPS estimate to $0.72 from $0.69. StockNews.com downgraded PBYI from "strong-buy" to "buy". PBYI opened at $2.88, with a market cap of $138.93M. PBYI reported ($0.09) EPS for Q2, beating estimates by $0.01. Director Michael Patrick Miller sold 23,358 shares at $3.49 each. Institutional investors own 61.29% of PBYI.

Zacks Research raised Puma Biotechnology's Q3 2026 EPS estimate to $0.24 from $0.22. StockNews.com downgraded PBYI from 'strong-buy' to 'buy'. Puma Biotechnology stock opened at $2.83, with a market cap of $136.52 million. The company reported Q2 EPS of ($0.09), beating estimates of ($0.10). Director Michael Patrick Miller sold 23,358 shares at $3.49 each.

This article explains Return On Equity (ROE) and uses Puma Biotechnology, Inc. as an example, calculating its ROE at 18%. It discusses the impact of debt on ROE and suggests further analysis for investors.

Squarepoint Ops LLC increased its stake in Puma Biotechnology by 17.7% in Q2, owning 71,391 shares worth $233,000. Several hedge funds also adjusted their holdings, with Acadian Asset Management LLC, Renaissance Technologies LLC, Great Point Partners LLC, American Century Companies Inc., and Dimensional Fund Advisors LP all making changes. Director Michael Patrick Miller and CEO Alan H. Auerbach sold shares in August and July, respectively. Puma Biotechnology's stock opened at $2.85 on Friday, with a market cap of $137.48 million. The company reported $0.09 EPS for Q2, beating estimates, and analysts predict $0.25 EPS for the current fiscal year. HC Wainwright maintained a 'buy' rating with a $7.00 target, while StockNews.com downgraded the rating to 'buy'.